Capricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD)
Capricor Therapeutics Announces HOPE-2 Trial Data Presentation On September 2nd, Capricor Therapeutics (NASDAQ: CAPR) announced an upcoming company…